
Reuters has reported that Eli Lilly launched Mounjaro in India in March 2025, and that multiple Indian drugmakers launched cheaper semaglutide versions in March 2026 after patent expiry. Treatment costs have dropped sharply, which is likely to make these drugs much more visible and much more widely discussed.
That is exactly why a calm, medically grounded guide is useful now.
Ozempic is not a casual wellness product. It is a prescription medicine from the semaglutide family, originally used in type 2 diabetes, and closely associated with weight loss because it reduces appetite and slows gastric emptying. Tirzepatide, sold as Mounjaro, works differently: it acts on both GIP and GLP-1 pathways, not just GLP-1. These medicines can help the right patient, but they are not for everyone, and they should not be started on the basis of social media excitement or price alone.
Short answer
Ozempic-type medicines can help some people lose weight, but they are prescription drugs, not beauty shortcuts. In India, access is expanding and prices are becoming more attractive, but the important questions are still the same: Who is a suitable candidate? What are the side effects? What happens if you stop? And what kind of monitoring should happen before and during treatment?
At SB Aesthetics, these conversations are becoming more common in Gurgaon and Delhi NCR. Patients are not only asking whether these drugs work. They are also asking what happens to the face, skin, muscle, and overall body contour after rapid weight loss. That is where medical weight loss and aesthetic planning often begin to overlap. SB Aesthetics positions medically reviewed education as part of care, and the clinic’s published trust signals include a medically reviewed footer and a multidisciplinary team listing.
This guide explains:
Ozempic is a brand name for semaglutide. Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. These medicines help regulate blood sugar, reduce appetite, and slow stomach emptying. That combination can make people feel full sooner and for longer, which is one reason they can support weight loss in appropriately selected patients.
Tirzepatide, sold as Mounjaro, is not exactly the same drug. It is a dual GIP and GLP-1 receptor agonist. In simple terms, that means it works through two pathways instead of one. That distinction matters medically, and it is part of why people should not treat all “weight-loss injections” as interchangeable.
This is where patients can get confused, because the answer has changed quickly.
As of March 2026, India has moved from anticipation to active rollout. Reuters reported that Eli Lilly launched Mounjaro in India in 2025, and that Indian drugmakers launched cheaper semaglutide products in March 2026 after semaglutide patent expiry.
Reuters also reported increased regulatory scrutiny around unauthorized sales and promotion once these cheaper products entered the market. So the bigger question is no longer just “Is it available?” but “What exactly is being sold, by whom, and under what medical supervision?”
Cost is one of the main reasons search interest is surging.
Reuters reported that newer generic semaglutide products in India were launched at prices ranging roughly from ₹750 to ₹4,200 per month, depending on brand and dosage, and that these launches could reduce treatment costs by around 70% compared with the original branded products.
Reuters separately reported that Mounjaro’s India launch had already triggered a wave of patient enquiries, in part because India pricing was far lower than typical U.S. pricing.
But “cheap” should not be confused with “simple.” If a patient needs regular reviews, dose escalation, lab work, nutrition guidance, and long-term follow-up, the real cost is broader than the price of the pen alone.
These medicines are not meant for every person who wants to lose a few kilos before an event.
Official prescribing information for tirzepatide indicates use in adults with obesity, or in some adults with overweight plus weight-related medical problems, alongside diet and physical activity. That is the clinical context. In real practice, candidacy depends on medical history, metabolic risk, current medications, gastrointestinal history, and the person’s ability to follow a longer-term plan.
This is also why “Can I take it even if I am not diabetic?” is not a yes-or-no social media question. The answer depends on whether a qualified doctor believes the medicine is appropriate and safe for your specific situation.
The most common side effects are gastrointestinal. Official prescribing information for tirzepatide lists nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia among the most common adverse reactions. Official semaglutide labeling also includes gastrointestinal side effects and warnings around pancreatitis, gallbladder disease, kidney injury related to dehydration, and thyroid C-cell tumor warnings.
There is another point that deserves more attention in India: weight loss is not the same as fat loss alone. Research reviews suggest semaglutide-associated weight loss can include some reduction in lean mass as well. A 2024 systematic review found that while fat loss was the main driver, lean-mass reductions were also seen in some studies, ranging from minimal to substantial proportions of total weight loss. Harvard Health has also highlighted that rapid weight loss can increase muscle loss and that resistance training, adequate protein, and a structured plan matter.
That does not make these medicines “bad.” It means they should not be treated as one-click solutions.
This is where a lot of preventable problems begin.
Once a medicine becomes trendy and more affordable, it often starts circulating through informal advice, beauty clinics, unauthorized sellers, and social media shortcuts. Reuters reported that India’s drug regulator tightened surveillance against unauthorized sales and misleading promotion after cheaper semaglutide launches. That response itself is a warning sign: unsupervised use is not a minor issue.
A proper prescription pathway should involve:
A good consultation should go beyond body weight alone.
Before prescribing, a doctor should review:
This is also where patients need honest expectations. These drugs can help some people significantly. But they do not replace nutrition, physical activity, or long-term follow-through. And they do not guarantee that the face, skin, or body will look the way a person expects after rapid weight loss.
At SB Aesthetics, Dr. Shilpi Bhadani’s verified background includes MBBS, MS in General Surgery, MCh in Plastic & Reconstructive Surgery, and a DAFPRS aesthetic surgery fellowship in Switzerland, with practice experience across Safdarjung Hospital, SGPGI, Medanta, and private cosmetic surgery roles.
That perspective matters here because patients do not experience weight loss only as a number. In clinic, they often experience it through the mirror: changes in facial volume, skin quality, neck definition, abdominal skin, and body contour.
A medically reviewed, candid conversation is often far more useful than trend-driven reassurance. That is one reason SB Aesthetics’ clinic pages explicitly frame content as patient education rather than a substitute for medical advice.
A patient should not treat this as a self-directed experiment.
A more cautious discussion is needed if there is:
Do not wait it out if symptoms become severe.
Seek prompt medical advice for:
It can be safe for the right patient under proper supervision, but that is very different from saying it is safe for everyone. These drugs are prescription medicines with real side effects and real contraindications. India’s regulator has already tightened surveillance around unauthorized sales and promotions after cheaper semaglutide launches, which shows that misuse is a genuine concern. A doctor should evaluate candidacy, not just demand for fast weight loss. Read Rapid Weight Loss After Ozempic-Type Drugs: What Happens to the Face, Skin, and Muscle to learn about it in depth.
Ozempic refers to semaglutide, while Mounjaro refers to tirzepatide. Semaglutide is a GLP-1 receptor agonist. Tirzepatide works through both GIP and GLP-1 pathways. They are both associated with weight loss, but they are not the same medicine and should not be discussed as if they are interchangeable. The decision between them depends on diagnosis, goals, side-effect profile, availability, and physician judgement.
Many patients do regain at least some weight after stopping weight-loss medication if the longer-term plan is weak. That is one reason doctors should discuss maintenance from the beginning, not only initiation. Treatment should sit inside a broader plan that includes nutrition, movement, metabolic follow-up, and realistic expectations. If someone starts only because the medicine is newly affordable, but has no plan beyond the first few months, rebound can become a real issue.
They can contribute to loss of lean mass along with fat loss, especially when weight comes down quickly and the person is not protecting muscle with an appropriate plan. A 2024 systematic review found lean-mass reductions across several semaglutide studies, and Harvard Health has emphasized that rapid weight loss can increase muscle loss. This is why “eat less and inject weekly” is not a complete strategy. Resistance work, protein planning, and follow-up matter.
Because in real practice, rapid weight loss and aesthetics often intersect. Patients may first search for the medicine, but later they ask about hollow cheeks, loose skin, facial aging, neck laxity, or abdominal contour changes. A plastic surgeon’s role is not to sell fear around weight loss. It is to explain anatomy, tissue changes, and what may or may not need treatment after weight changes. That is part of patient education, and SB Aesthetics explicitly frames its website content in that educational, medically reviewed way.
SB AESTHETICS CENTRE TIMINGS
Monday - Sunday: 8:30AM - 7:00PM
SB Aesthetics is one of the renowned medical centers in Gurgaon offering world-class and most advanced plastic surgeries procedures under the guidance of Dr. Shilpi Bhadani.
Disclaimer: The content on this website (www.drshilpibhadani.com) is solely for the purpose of educating and creating awareness about the domain i.e. plastic surgery. This shall not be treated as a substitute to a professional plastic surgeon's advice or prescription. Every individual and their case is different, so the results of any of the treatments mentioned on the website may vary.